Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. have extended the U.S. portion of their development and commercialization agreement for Abilify (aripiprazole), which was scheduled to end in November 2012, until the drug’s expected loss of exclusivity in April 2015. The companies have also established an oncology collaboration for two BMS products, Sprycel (dasatinib) and Ixempra (ixabepilone). Under terms of the agreement, Otsuka will receive an up-front cash payment of $400 million....